TGA clarifies NAD+ precursor labelling for Australian supplement market
Australia's TGA has issued specific guidance on naming and labelling for NMN, NAD+, NAD, and NADH products, impacting market access and competition. Brands must navigate strict compliance, particularly for ingredients beyond NMN, to avoid regulatory challenges.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Canberra, Australia — 01 September 2026
Australia's Therapeutic Goods Administration (TGA) has released definitive guidance on the representation of nicotinamide adenine dinucleotide (NAD+) precursor ingredients in complementary medicines. This updated directive specifies naming, labelling, and advertising requirements for NMN, NAD+, NAD, and NADH products. Crucially, while NMN, nicotinamide, and nicotinamide riboside chloride (NR) are permitted, NAD, NAD+, and NADH themselves are not yet approved for use in Australia's regulated supplement market. This creates a regulatory dichotomy: permitted precursors face strict labelling rules, while direct NAD forms remain prohibited.
The TGA's stance has direct implications for supplement manufacturers and brand owners operating within Australia. Brands utilising permitted NAD+ precursors must ensure their product naming and marketing materials align precisely with the new guidance. Any product containing unapproved NAD-related compounds for sale within Australia is subject to compliance action. This regulatory clarity aims to address a persistent market disparity where Australian businesses, investing heavily in TGA compliance, compete against imported products from channels like cross-border e-commerce, which operate under different regulatory frameworks.
NAD+ precursor ingredients have experienced rapid growth across the Asia-Pacific region, driven by consumer interest in anti-ageing and longevity claims. Prior to last year's approval of NMN, Australian consumers frequently accessed these products via personal importation schemes. Rhiona Robertson, General Manager at Healthcare Product Specialists, highlights the uneven playing field: "Australian businesses invest significantly in regulatory compliance, local manufacturing, packaging, and marketing, while competing for the same consumer against imported products operating under very different regulatory requirements." This disparity impacts local producers' ability to recoup compliance costs and maintain competitive pricing.
What this means for Australia
Australian supplement manufacturers must immediately review their NAD+ precursor product portfolios for compliance with the TGA's new labelling guidance. Reformulation may be required for products misrepresenting non-permitted NAD-related compounds, leading to significant R&D and packaging costs. Brand owners should prepare for increased TGA scrutiny on marketing claims, particularly regarding anti-ageing benefits. Procurement teams must verify ingredient supply chain compliance, ensuring only approved NMN, nicotinamide, or NR are used. This regulatory environment offers compliant domestic brands a competitive advantage against less scrupulous grey market imports, provided the TGA enforces rigorously.
The TGA's guidance reinforces the need for rigorous scientific substantiation for all novel ingredients. The burgeoning interest in sexual wellness supplements, noted by Lelo's survey indicating 44% of US consumers are interested in supplements crossing beauty and sexual wellness, further underscores this. As new categories emerge, regulatory bodies will increase scrutiny on claims and ingredient safety. Brands planning new product development in these areas must proactively secure robust clinical evidence, as market expansion will invariably trigger heightened regulatory oversight.
Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.